Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 16:10 ET
|
Aerpio Pharmaceuticals, Inc.
Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the...
Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
June 04, 2021 09:15 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company...
Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
May 19, 2021 19:52 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on...
Aerpio Reports First Quarter 2021 Financial Results and Provides Business Update
May 17, 2021 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
Ended first quarter 2021 with $39.0 million in cash and cash equivalents Subsequent to March 31, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc. CINCINNATI, May ...
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
May 17, 2021 07:00 ET
|
Aerpio Pharmaceuticals, Inc.
Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genesConcurrent $155 million...
Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 11, 2021 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
Ended fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategic alternatives focused on maximizing stockholder value from existing...
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
March 05, 2021 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
SAN FRANCISCO and CINCINNATI, March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the...
Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
January 05, 2021 16:01 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2,...
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial
December 11, 2020 17:00 ET
|
Aerpio Pharmaceuticals, Inc.
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues in both COVID-19 clinical trials ...
Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update
November 10, 2020 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021Initiated second clinical trial to...